OncLive | Bringing the Global Oncology Community Together

The FDA has approved talazoparib (Talzenna) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Read More >>

Testing Reveals Extent of Lynch Syndrome

Step Therapy Policy Alarms Cancer Leaders

Combinations With RT May Improve Immunotherapy Response

Specialization Trend Is Changing the Oncology Landscape

Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial

View More Stories >>

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

2018 Lynn Sage Breast Cancer Symposium

Dr. Yardley on the FDA Approval of Talazoparib in Breast Cancer

Dr. Kerr on Misconceptions With Molecular Profiling in Lung Cancer

$Dr. Wang Discusses the Treatment of Relapsed/Refractory MCL$

Dr. Wang Discusses the Treatment of Relapsed/Refractory MCL

Dr. Meeks Discusses Smoking Status in Bladder Cancer

Dr. Horn Discusses Next Steps With Atezolizumab in SCLC

Dr. Andreadis on Response to CAR T-Cell Therapy

Dr. Lenz on the Changing Landscape of Metastatic Colorectal Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Perspectives on the Future Treatment of HCC

Anti-VEGF Therapy in Metastatic HCC

Locally Advanced NSCLC: Approaching the PACIFIC Trial

Multitargeted TKI Therapy in Metastatic HCC

Checkpoint Inhibitors Versus TKI Therapy in HCC

Immunotherapy in Second-Line Metastatic HCC

Appropriateness for Regorafenib in Metastatic HCC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Future Treatment Approaches to AML

Moving the AML Treatment Landscape Forward

Optimizing the Use of FLT3 Inhibitor Therapy for AML

Long-Term Challenges With FLT3 Inhibition in AML

Testing for FLT3 Mutations in the Community Setting of AML

Quizartinib's Potential Role in Treating AML

Personal Experience Managing AML With Quizartinib

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

Expert Anticipates Cure in Acute Lymphoblastic Leukemia

Elias Jabbour, MD, discussed recent clinical trial results in acute lymphoblastic leukemia, the role of immunotherapy, and the biggest challenges facing the field.

View more >>>

Featured

Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Radhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.

View more >>>

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals of HPV Vaccine and NGS Assay, Priority Review in Myeloma, and More